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98Mode of Death Prevention
by SerelaxinWe read with interest the article by Felker et al. (1)
regarding the effect of serelaxin on the mode of death
prevention in acute heart failure. This paper was a
subgroup analysis of the RELAX-AHF (Efﬁcacy and
Safety of Relaxin for the Treatment of Acute Heart
Failure) study intended to assess the effect of ser-
elaxin on the speciﬁc mode of death in acute heart
failure patients enrolled in the trial. The RELAX-AHF
study demonstrated a reduction in the secondary
endpoint of 180-day mortality in patients receiving a
48-h continuous infusion of 30 mg/kg/day serelaxin
compared with placebo (2). Although designed for the
treatment of acute heart failure, the mortality beneﬁt
observed with serelaxin treatment was driven by re-
ductions in sudden cardiac death and other cardio-
vascular deaths, speciﬁcally stroke, whereas there
was no difference in death due to heart failure.
The study authors note that multiple mechanisms
contribute to sudden cardiac death in heart failure,
and serelaxin modulates a variety of biological path-
ways relevant to sudden cardiac death. The authors
describe the reduction in the rate of fatal stroke as an
“unexpected ﬁnding.” The accompanying editorial (3)
notes that although these results “are encouraging, it
is difﬁcult to reconcile the main mortality ﬁndings of
the RELAX-AHF trial with those of the current HF
treatment paradigm because no short-term therapy
for hospitalized or chronic HF has previously de-
monstrated long-term beneﬁt.” Given the relatively
small number of deaths in the RELAX-AHF trial
(n ¼ 107), it is possible that these differences are due
to chance alone and will not be observed in the larger
phase III serelaxin trial. However, there may be a
plausible biological mechanism to explain these
results.
We previously showed that in a spontaneously
hypertensive rat model, which is highly susceptible
to inducible atrial ﬁbrillation, a 14-day treatment
with continuous subcutaneous administration of
400 mg/kg/day of relaxin was able to suppress in-
ducible atrial ﬁbrillation (4). Examination of the ef-
fects of relaxin on the heart revealed that relaxin was
able to improve the pathological structural and elec-
trical remodeling present in spontaneously hyper-
tensive rat hearts. The relaxin-treated rats had
a signiﬁcant reversal of cardiac ﬁbrosis and car-
diomyocyte hypertrophy. In addition to reversing
pathological structural remodeling, relaxin in-
creased cardiac conduction velocity. The increase inconduction velocity was not only secondary to the
reversal of ﬁbrosis but also an increase in the sodium
current density (INa) caused by an up-regulation in the
expression of voltage-gated Naþ channels (electrical
remodeling). To extend human relevance to our rat
model, we demonstrated that these electrical remod-
eling changes also occur in human cardiomyocytes
derived from inducible pluripotent stem cells after
only 24 to 48 h of relaxin exposure. It is important to
note that our rat model received a higher dose of
subcutaneously administered relaxin for 2 weeks, and
regression of ﬁbrosis was not seen within 48 h.
It is plausible that the observed reduction in sud-
den cardiac death and stroke in the RELAX-AHF trial
could be explained by serelaxin-induced structural
and electrical remodeling. Cardiac ﬁbrosis and slow-
ing of conduction velocity have been associated with
increased risk of atrial and ventricular arrhythmias.
It is possible that serelaxin decreased the risk of
sudden cardiac death by improving cardiac conduc-
tion velocity in human heart failure patients through
increasing INa and/or decreasing ﬁbrosis. The unex-
pected reduction in fatal stroke could be explained
by suppression of atrial ﬁbrillation. It would be
interesting to compare cardiac magnetic resonance
images from patients before and after serelaxin
treatment to better understand the antiﬁbrotic ef-
fects of serelaxin, should a 2-day treatment be
sufﬁcient to reverse ﬁbrosis. It would be valuable
to interrogate implantable cardiac devices to
quantify atrial and ventricular arrhythmia burden.
It is not clear from the published literature whether
these data exist, but we do know that approxi-
mately one-half of the RELAX-AHF patients had
atrial ﬁbrillation and >20% had a pacemaker or
implantable cardioverter-deﬁbrillator (2). We eagerly
await results from future serelaxin studies and
hope that the investigators consider the antiﬁbrotic
and antiarrhythmic effects of serelaxin in future
analyses.*Brian L. Henry, MD, PhD
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We thank Dr. Henry and colleagues for their interest
in our study on the mode of death in the RELAX-AHF
(Efﬁcacy and Safety of Relaxin for the Treatment of
Acute Heart Failure) study of serelaxin in acute heart
failure (1). The authors provide very interesting data
from their own laboratory on the possible role of
serelaxin in modulating cardiac ﬁbrosis, myocyte
hypertrophy, and cardiac conduction (2) and specu-
late that these mechanisms may be potential expla-
nations for the reduction in sudden death and fatal
stroke observed with serelaxin treatment in the
RELAX-AHF study.
As the authors point out, there are substantial
differences in dose, duration of exposure, and disease
state between their experimental model and our
clinical trial results, making it difﬁcult to draw any
deﬁnitive conclusions about the possible role of these
mechanisms in our ﬁndings. Importantly, however,
their data do underscore the pleiotropic nature of the
biological effects of relaxin (3), which may in part
explain the favorable impact of serelaxin therapy onclinical outcomes (4) and end-organ function (5) seen
in the RELAX-AHF study. As noted, the ongoing
RELAX-AHF2 (Efﬁcacy, Safety and Tolerability of
Serelaxin When Added to Standard Therapy in AHF)
study (NCT01870778) will provide more deﬁnitive
data on the efﬁcacy of serelaxin in acute heart failure.
The interesting data provided by Dr. Henry and col-
leagues suggest additional avenues of research for the
potential role of serelaxin in the treatment of car-
diovascular disease.*G. Michael Felker, MD, MHS
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